BR0017136A - Peptìdeos de ligação ao hla e seus usos. - Google Patents

Peptìdeos de ligação ao hla e seus usos.

Info

Publication number
BR0017136A
BR0017136A BR0017136-0A BR0017136A BR0017136A BR 0017136 A BR0017136 A BR 0017136A BR 0017136 A BR0017136 A BR 0017136A BR 0017136 A BR0017136 A BR 0017136A
Authority
BR
Brazil
Prior art keywords
hla
peptides
binding peptides
allele
binding
Prior art date
Application number
BR0017136-0A
Other languages
English (en)
Inventor
Alessandro Sette
John Sidney
W Martin Kast
Scott Southwood
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of BR0017136A publication Critical patent/BR0017136A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PEPTìDEOS DE LIGAçãO AO HLA E SEUS USOS". A presente invenção proporciona os meios e os métodos para selecionar peptídeos imunogênicos e as composições de peptídeos imunogênicos capazes de ligar especificamente glicoproteínas codificadas por alelos de HLA e induzir a ativação das células T em células T restringidas pelo alelo. Os peptídeos são úteis para fazer surgir uma resposta imunológica contra um antígeno desejado.
BR0017136-0A 2000-02-23 2000-02-23 Peptìdeos de ligação ao hla e seus usos. BR0017136A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/004655 WO2001062776A1 (en) 2000-02-23 2000-02-23 Hla binding peptides and their uses

Publications (1)

Publication Number Publication Date
BR0017136A true BR0017136A (pt) 2003-02-25

Family

ID=21741082

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0017136-0A BR0017136A (pt) 2000-02-23 2000-02-23 Peptìdeos de ligação ao hla e seus usos.

Country Status (8)

Country Link
EP (1) EP1263775A4 (pt)
JP (1) JP2003524016A (pt)
CN (1) CN1452634A (pt)
AU (1) AU2000232427A1 (pt)
BR (1) BR0017136A (pt)
CA (1) CA2400215A1 (pt)
MX (1) MXPA02008219A (pt)
WO (1) WO2001062776A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000225A1 (en) * 1999-06-29 2001-01-04 Epimmune Inc. Hla binding peptides and their uses
AU2001242190A1 (en) * 2000-03-31 2001-10-15 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US8354380B2 (en) 2004-06-17 2013-01-15 Mannkind Corporation NY-ESO-1 peptide analogs
JP4475469B2 (ja) * 2005-01-25 2010-06-09 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
KR20080026181A (ko) * 2005-06-17 2008-03-24 맨카인드 코포레이션 암세포 및 종양 기질에 발현된 우성 및 준우성 에피토프에대한 다가 면역반응을 유발하기 위한 방법 및 조성물
US7511118B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
CN1948333B (zh) * 2005-10-14 2010-12-08 中国人民解放军第二军医大学 一种新的hPEBP4蛋白来源的HLA-A2限制性表位多肽及其应用
WO2008031064A1 (en) * 2006-09-07 2008-03-13 University Of South Florida Hyd1 peptides as anti-cancer agents
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
CA2793838C (en) 2010-03-19 2019-09-17 H. Lee Moffitt Cancer Center & Research Institute, Inc. Integrin interaction inhibitors for the treatment of cancer
US20130183376A1 (en) * 2010-09-08 2013-07-18 Saitama Medical University Hepatitis c virus liposome vaccine
WO2015048477A1 (en) 2013-09-27 2015-04-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cyclic peptide conjugates and methods of use
CN110049774A (zh) 2016-10-07 2019-07-23 恩特罗姆公司 肿瘤相关抗原表位的小型生物群序列变体
EP3522916A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
EP3522915A2 (en) 2016-10-07 2019-08-14 Enterome S.A. Immunogenic compounds for cancer therapy
SG11201901979SA (en) 2016-11-30 2019-04-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CA3081710A1 (en) * 2017-11-08 2019-05-16 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
EP3773689B1 (en) 2018-04-11 2022-11-09 Enterome S.A. Antigenic peptides for prevention and treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE466869T1 (de) * 1993-03-05 2010-05-15 Epimmune Inc Verfahren zur herstellung von immunogenen hla- a2.1-bindenden peptiden
EP0907370B1 (en) * 1996-03-21 2005-05-25 Epimmune Inc. Hla-a2.1 binding peptides and their uses
AU3672597A (en) * 1996-07-25 1998-02-20 Johns Hopkins University, The Novel genes of kaposi's sarcoma associated herpesvirus
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid

Also Published As

Publication number Publication date
JP2003524016A (ja) 2003-08-12
WO2001062776A1 (en) 2001-08-30
AU2000232427A1 (en) 2001-09-03
MXPA02008219A (es) 2005-06-30
CA2400215A1 (en) 2001-08-30
CN1452634A (zh) 2003-10-29
EP1263775A4 (en) 2004-10-06
EP1263775A1 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
BR9708220A (pt) Peptìdios de ligação hla-a2.1 e seus usos
BR9406652A (pt) Composição
AU2001298049A1 (en) Hla class i and ii binding peptides and their uses
ATE512666T1 (de) Hla-bindende peptide und ihre verwendungen
DK0941478T3 (da) Assaymetode for peptidspecifikke T-celler
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
ES2184769T3 (es) Metodos y composiciones para microencapsulacion de antigenos para utilizar como vacunas.
BR9610802A (pt) Método para melhoria da resposta imunológica método de preparo de células t de antígeno específico método para induzir tolerância de tecido de enxerto auxiliar de vacina meio de expansão e preparação de células dentríticas população de células dentríticas e respectivo método de preparo método para direcionar células-tronco hematopoiéticas ou células progenitoras a uma linhagem de células dentríticas
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
DK1267924T3 (da) Immunterapeutiske metoder og sammensætninger
PT1272633E (pt) Composições e métodos para imunoterapia baseada em células dendríticas
DE69720065D1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
DE69940774D1 (de) Hla-bindende peptide und ihre verwendungen
AP2368A (en) Novel expression vectors and uses thereof.
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
AU2000273396A1 (en) Hla binding peptides and their uses
WO1999047102A3 (en) Methods for enhanced antigen presentation on antigen-presenting cells and compositions produced thereby
ATE353226T1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
WO2002044205A3 (en) Peptides from ag85 of mycobacterium and uses thereof
BR0016740A (pt) Antìgenos de esporozoìto de cryptosporidium

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]